Literature DB >> 6230181

Cell-mediated immunodeficiency in Down's syndrome: normal IL-2 production but inverted ratio of T cell subsets.

R Karttunen, T Nurmi, J Ilonen, H M Surcel.   

Abstract

To get more information on the mechanism of cell-mediated immunodeficiency associated with Down's syndrome, 18 patients were studied for PHA-induced lymphocyte transformation and interleukin-2 (IL-2) production. A normal amount of IL-2 was produced although half of the patients showed decreased blast transformation. T cell subpopulations were studied in some patients with decreased and with normal blast transformation. All studied patients with decreased blast transformation had inverted helper/suppressor T cell ratio.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6230181      PMCID： PMC1535811     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


  26 in total

1.  Immunologic characteristics of Down's syndrome.

Authors:  M E Gershwin; F M Crinella; J J Castles; J K Trent
Journal:  J Ment Defic Res       Date:  1977-12

2.  On the influence of age on immunity in Down's syndrome.

Authors:  R Seger; G Buchinger; J Ströder
Journal:  Eur J Pediatr       Date:  1977-01-26       Impact factor: 3.183

3.  Monoclonal antibodies defining distinctive human T cell surface antigens.

Authors:  P Kung; G Goldstein; E L Reinherz; S F Schlossman
Journal:  Science       Date:  1979-10-19       Impact factor: 47.728

4.  T-lymphocyte function and sensitivity to interferon in trisomy 21.

Authors:  L B Epstein; C J Epstein
Journal:  Cell Immunol       Date:  1980-05       Impact factor: 4.868

5.  Immunodeficiency in Down's syndrome: low levels of serum thymic factor in trisomic children.

Authors:  M Duse; M A Brugo; A Martini; C Tassi; C Ferrario; A G Ugazio
Journal:  Thymus       Date:  1980-12

6.  Immunological studies of aging. Decreased production of and response to T cell growth factor by lymphocytes from aged humans.

Authors:  S Gillis; R Kozak; M Durante; M E Weksler
Journal:  J Clin Invest       Date:  1981-04       Impact factor: 14.808

7.  The cellular basis for viral-induced immunodeficiency: analysis by monoclonal antibodies.

Authors:  E L Reinherz; C O'Brien; P Rosenthal; S F Schlossman
Journal:  J Immunol       Date:  1980-09       Impact factor: 5.422

8.  Thymic deficiency in Down's syndrome.

Authors:  S Levin; M Schlesinger; Z Handzel; T Hahn; Y Altman; B Czernobilsky; J Boss
Journal:  Pediatrics       Date:  1979-01       Impact factor: 7.124

9.  T and B lymphocytes in patients with Down's syndrome.

Authors:  K Reiser; C Whitcomb; K Robinson; M R MacKenzie
Journal:  Am J Ment Defic       Date:  1976-05

10.  Altered cellular immune functions in patients with Down's syndrome.

Authors:  C A Spina; D Smith; E Korn; J L Fahey; H J Grossman
Journal:  Am J Dis Child       Date:  1981-03
View more
  10 in total

1.  Immunoregulatory CD4+ CD45R+ suppressor/inducer T lymphocyte subsets and impaired cell-mediated immunity in patients with Down's syndrome.

Authors:  S Raziuddin; M E Elawad
Journal:  Clin Exp Immunol       Date:  1990-01       Impact factor: 4.330

2.  Analysis of impaired in vitro immunoglobulin synthesis in rheumatoid arthritis.

Authors:  I Jokinen; K Poikonen; T Möttönen; P Hannonen; M Oka; J Ilonen; H M Surcel; R Karttunen; H Arvilommi
Journal:  Ann Rheum Dis       Date:  1990-07       Impact factor: 19.103

3.  Interleukin 2 and gamma interferon production, interleukin 2 receptor expression, and DNA synthesis induced by tularemia antigen in vitro after natural infection or vaccination.

Authors:  R Karttunen; G Andersson; H P Ekre; K Juutinen; H M Surcel; H Syrjälä; E Herva
Journal:  J Clin Microbiol       Date:  1987-06       Impact factor: 5.948

4.  T cell response to anti-CD3 antibody in Down's syndrome.

Authors:  A Bertotto; C Arcangeli; S Crupi; I Marinelli; R Gerli; R Vaccaro
Journal:  Arch Dis Child       Date:  1987-11       Impact factor: 3.791

5.  Interleukin 2 production in whole blood culture: a rapid test of immunity to Francisella tularensis.

Authors:  R Karttunen; J Ilonen; E Herva
Journal:  J Clin Microbiol       Date:  1985-08       Impact factor: 5.948

6.  Cell-mediated cytotoxicity in Down syndrome: impairment of allogeneic mixed lymphocyte reaction, NK and NK-like activities.

Authors:  D Montagna; R Maccario; A G Ugazio; L Nespoli; E Pedroni; P Faggiano; G R Burgio
Journal:  Eur J Pediatr       Date:  1988-10       Impact factor: 3.183

7.  Interleukin 2 activity in chronic liver disease and the effect of in vitro alpha-interferon.

Authors:  S Saxena; K T Nouri-Aria; M G Anderson; A L Eddleston; R Williams
Journal:  Clin Exp Immunol       Date:  1986-03       Impact factor: 4.330

8.  The first case of isolated facial cutanenous leishmaniasis in a Down syndrome infant: a case report and review of the literature.

Authors:  Kotb Abass; Hekma Saad; Alaa A Abd-Elsayed
Journal:  Cases J       Date:  2009-01-06

Review 9.  Down syndrome, accelerated aging and immunosenescence.

Authors:  Noémie Gensous; Maria Giulia Bacalini; Claudio Franceschi; Paolo Garagnani
Journal:  Semin Immunopathol       Date:  2020-07-23       Impact factor: 9.623

10.  Stem cell deficiencies and thymic abnormalities in fetal mouse trisomy 16.

Authors:  C J Epstein; B G Hofmeister; D Yee; S A Smith; R Philip; D R Cox; L B Epstein
Journal:  J Exp Med       Date:  1985-08-01       Impact factor: 14.307
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.